Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 7,866 matching trials from the live ClinicalTrials.gov search.

Filters: Minneapolis, Minnesota Clear all

Conditions: Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: 3-Dimensional Conformal Radiation Therapy, Apalutamide, Computed Tomography, Degarelix, External Beam Radiation Therapy, Fluciclovine F18, Goserelin Acetate, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy, Leuprolide Acetate, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Relugolix, Stereotactic Body Radiation Therapy, Triptorelin, Volume Modulated Arc Therapy; Radiation · Drug · Procedure + 1 more
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 804 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2032
U.S. locations: 341
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 240 more

Conditions: Breast Carcinoma, Fallopian Tube Carcinoma, Ovarian Neoplasm, Primary Peritoneal Carcinoma
Interventions: Evaluation of Cancer Risk Factors, Quality-of-Life Assessment, Questionnaire Administration, Study of High Risk Factors; Procedure · Other
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 30 Years and older · Female only
Enrollment: 1,916 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 141
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 106 more

Conditions: Primary Biliary Cholangitis
Interventions: Seladelpar 10 mg, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 43
States / cities: Chandler, Arizona • Pasadena, California • Sacramento, California + 32 more

Conditions: Diagnostic Tests
Interventions: Not listed
Lead sponsor: Radiometer Medical ApS; Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hepatocellular Carcinoma, Bilirubinemia
Interventions: Transarterial chemoembolization; Combination Product
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Neurotypical, Cognitively Normal
Interventions: aerobic exercise; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 21 Years to 95 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Stress, Stress Disorder, Stress, Psychological, Trauma, Psychological, Anxiety, Anxiety State, Post Traumatic Stress Disorder, Secondary Traumatic Stress, Professional Quality of Life, Stress Related Disorder, Stress Reaction, Stress Risk, Mental Resilience, Emotional Resilience
Interventions: MinnRAP Peer Support Program; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Chronic Kidney Disease
Interventions: Empagliflozin, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 25
States / cities: Birmingham, Alabama • Palo Alto, California • Sacramento, California + 22 more

Conditions: Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With, Glucocorticoid-induced Osteoporosis
Interventions: Denosumab, Placebo; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 6
States / cities: Los Angeles, California • Wilmington, Delaware • Indianapolis, Indiana + 3 more

Conditions: Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Docetaxel, Echocardiography Test, Gemcitabine Hydrochloride, Nab-paclitaxel, Nivolumab, Paclitaxel, Ramucirumab; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 611
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 392 more

Conditions: Chemotherapeutic Agent Toxicity, Neuropathy, Neurotoxicity Syndrome, Pain, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer
Interventions: Carboplatin, Glutathione, Laboratory Biomarker Analysis, Paclitaxel, Placebo, Quality-of-Life Assessment; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 390
States / cities: Mobile, Alabama • Fairbanks, Alaska • Scottsdale, Arizona + 259 more

Conditions: Healthy
Interventions: Foods with beta-glucan from oats and barley; Other
Lead sponsor: General Mills; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Obesity, Diet Modification
Interventions: Dietary Counseling; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Juvenile Idiopathic Arthritis
Interventions: CP-690,550; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 4
States / cities: Minneapolis, Minnesota • Cincinnati, Ohio • Portland, Oregon

Conditions: Hypertension
Interventions: Geneticure Panel for HTN therapy, JNC-8; Drug
Lead sponsor: Geneticure, LLC; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 15
States / cities: Andover, Minnesota • Blaine, Minnesota • Bloomington, Minnesota + 12 more

Conditions: Leukemia
Interventions: clofarabine, cytarabine, methotrexate, laboratory biomarker analysis; Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 30 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 74
States / cities: Birmingham, Alabama • Downey, California • Long Beach, California + 65 more

Conditions: Colorectal Neoplasms
Interventions: Blood draw; Procedure
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 29
States / cities: Mobile, Alabama • Tucson, Arizona • Fresno, California + 26 more

Conditions: HIV Infections
Interventions: Lopinavir/Ritonavir, Nevirapine; Drug
Lead sponsor: Abbott; Industry
Eligibility: 12 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 46
States / cities: Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 33 more

Conditions: HIV Infections
Interventions: Tenofovir disoproxil fumarate; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 0 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 19
States / cities: Berkeley, California • Los Angeles, California • San Francisco, California + 16 more

Conditions: Obstructive Hypertrophic Cardiomyopathy (oHCM)
Interventions: Aficamten (5 mg, 10 mg, 15 mg, and 20 mg), Placebo to match aficamten; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 48
States / cities: Anchorage, Alaska • La Jolla, California • Los Angeles, California + 39 more

Conditions: Auditory Hallucinations, Schizophrenia
Interventions: Active tDCS, Sham tDCS; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 45 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hepatic Impairment
Interventions: osilodrostat; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • Minneapolis, Minnesota

Conditions: Chronic GVHD
Interventions: Sirolimus + calcineurin inhibitor + prednisone, Sirolimus + prednisone; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: Not listed
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 31
States / cities: Duarte, California • La Jolla, California • Stanford, California + 27 more

Conditions: Stage IV Melanoma, Stage III Melanoma, Recurrent Melanoma
Interventions: allovectin-7, allovectin-7/dacarbazine, dacarbazine; Drug
Lead sponsor: Vical; Industry
Eligibility: 18 Years and older
Timeline: 1998 – 2002
U.S. locations: 44
States / cities: Little Rock, Arkansas • Bakersfield, California • Encinitas, California + 39 more

Search by objective public record fields.

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer

Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)

AQT90 FLEX NTproBNP2 Test Kit Matrix Comparison and Sample Stability Verification Study

Safety of Transarterial Chemoembolization (TACE) in the Setting of an Elevated Bilirubin

Brain Vascular and Neural Function Linked to Balance Across the Adult Lifespan

The Professional Peer Resilience Initiative

A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

Safety and Efficiency of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis

Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer

Beta-glucan, Product Claims and Satiety

Metabolic Impact of Time Restricted Feeding

Pharmacokinetics Of CP-690,550 In Pediatric Patients With Juvenile Idiopathic Arthritis (JIA)

Investigating the Use of Genetics to Guide Pharmacologic Therapy for Hypertension

Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Pharmacogenomics Blood Sampling Protocol For Irinotecan/Fluorouracil/Leucovorin(CPT-11/FU/LV).

A Study to Compare Two Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Previously Received Anti-HIV Treatment

The Safety of Tenofovir Disoproxil Fumarate Taken With Other Anti-HIV Drugs to Treat HIV-Infected Patients

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM

Non-Invasive Brain Stimulation for Medication-Resistant Auditory Hallucinations in Schizophrenia Patients

A Phase 1 Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Hepatic Function

Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)

Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma